-The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and older in Germany-<\/i><\/p>\n
BOSTON–(BUSINESS WIRE<\/a>)–Vertex Pharmaceuticals Incorporated<\/a> (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR\/Cas9 gene-edited therapy, CASGEVY\u00ae<\/sup> (exagamglogene autotemcel). This agreement secures sustainable access to this innovative one-time treatment for eligible patients in Germany ages 12 years and older living with severe sickle cell disease or transfusion-dependent beta thalassemia.<\/p>\n \n\u201cFor the first time in Germany, a long-term, sustainable access agreement to a gene therapy has been established for people living with sickle cell disease and transfusion-dependent beta thalassemia,\u201d said Ludovic Fenaux, Senior Vice President, Vertex International. \u201cThis agreement represents significant progress for people living with these two devastating and life-shortening diseases. We are pleased to collaborate across the health care system to ensure the value of CASGEVY is recognized and sustainable patient access is secured.\u201d<\/p>\n \nWith this agreement, Germany joins a growing number of countries that have reimbursed CASGEVY, including Austria, Denmark, Italy, the Kingdom of Saudi Arabia, the United Arab Emirates, the United Kingdom and the United States. Vertex remains committed to working with government and reimbursement authorities globally to ensure sustainable access for eligible patients.<\/p>\n About Sickle Cell Disease (SCD)<\/b><\/p>\n \nSCD is a debilitating, progressive, life-shortening genetic disease. SCD patients report health-related quality of life scores well below the general population and significant health care resource utilization. SCD affects the red blood cells, which are essential for carrying oxygen to all organs and tissues of the body. SCD causes severe pain, organ damage and shortened life span due to misshapen or \u201csickled\u201d red blood cells. The clinical hallmark of SCD is vaso-occlusive crises (VOCs), which are caused by blockages of blood vessels by sickled red blood cells and result in severe and debilitating pain that can happen anywhere in the body at any time. SCD requires lifelong treatment and significant use of health care resources, and ultimately results in reduced life expectancy, decreased quality of life and reduced lifetime earnings and productivity. In Europe, the mean age of death for patients living with SCD is around 40 years.<\/p>\n About Transfusion-Dependent Beta Thalassemia (TDT)<\/b><\/p>\n \nTDT is a serious, life-threatening genetic disease. TDT patients report health-related quality of life scores below the general population and significant health care resource utilization. TDT requires frequent blood transfusions and iron chelation therapy throughout a person\u2019s life. Due to anemia, patients living with TDT may experience fatigue and shortness of breath, and infants may develop failure to thrive, jaundice and feeding problems. Complications of TDT can also include an enlarged spleen, liver and\/or heart, misshapen bones and delayed puberty. TDT requires lifelong treatment and significant use of health care resources, and ultimately results in reduced life expectancy, decreased quality of life and reduced lifetime earnings and productivity. In Europe, the mean age of death for patients living with TDT is 50-55 years.<\/p>\n About CASGEVY\u00ae<\/sup> (exagamglogene autotemcel)<\/b><\/p>\n \nCASGEVY\u00ae<\/sup> is a non-viral, ex vivo<\/i> CRISPR\/Cas9 gene-edited cell therapy for eligible patients with SCD or TDT, in which a patient\u2019s own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A<\/i> gene through a precise double-strand break. This edit results in the production of high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the oxygen-carrying hemoglobin that is naturally present during fetal development, which then switches to the adult form of hemoglobin after birth. CASGEVY has been shown to reduce or eliminate VOCs for patients with SCD and transfusion requirements for patients with TDT.<\/p>\n \nCASGEVY is approved for eligible SCD and TDT patients 12 years and older by multiple regulatory bodies around the world. In the European Union, CASGEVY is approved for patients 12 years of age and older with either severe SCD with recurrent VOCs or TDT, for whom hematopoietic stem cell (HSC) transplantation is appropriate and a human leukocyte antigen matched related HSC donor is not available.<\/p>\n \nFor complete product information, please see the Summary of Product Characteristics (SmPC) at www.ema.europa.eu<\/a>.<\/p>\n U.S. INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR CASGEVY<\/b><\/p>\n WHAT IS CASGEVY?<\/b><\/p>\n \nCASGEVY is a one-time therapy used to treat people ages 12 years and older with:<\/p>\n \nCASGEVY is made specifically for each patient, using the patient\u2019s own edited blood stem cells, and increases the production of a special type of hemoglobin called hemoglobin F (fetal hemoglobin or HbF). Having more HbF increases overall hemoglobin levels and has been shown to improve the production and function of red blood cells. This can eliminate VOCs in people with sickle cell disease and eliminate the need for regular blood transfusions in people with beta thalassemia.<\/p>\n IMPORTANT SAFETY INFORMATION<\/b><\/p>\n What is the most important information I should know about CASGEVY?<\/b><\/p>\n \nAfter treatment with CASGEVY, you will have fewer blood cells for a while until CASGEVY takes hold (engrafts) into your bone marrow. This includes low levels of platelets (cells that usually help the blood to clot) and white blood cells (cells that usually fight infections). Your doctor will monitor this and give you treatment as required. The doctor will tell you when blood cell levels return to safe levels.<\/p>\n \nYou may experience side effects associated with other medicines administered as part of the treatment regimen for CASGEVY. Talk to your physician regarding those possible side effects. Your healthcare provider may give you other medicines to treat your side effects.<\/p>\n How will I receive CASGEVY?<\/b><\/p>\n \nYour healthcare provider will give you other medicines, including a conditioning medicine, as part of your treatment with CASGEVY. It\u2019s important to talk to your healthcare provider about the risks and benefits of all medicines involved in your treatment.<\/p>\n \nAfter receiving the conditioning medicine, it may not be possible for you to become pregnant or father a child. You should discuss options for fertility preservation with your healthcare provider before treatment.<\/p>\n STEP 1:<\/b> Before CASGEVY treatment, a doctor will give you mobilization medicine(s). This medicine moves blood stem cells from your bone marrow into the blood stream. The blood stem cells are then collected in a machine that separates the different blood cells (this is called apheresis). This entire process may happen more than once. Each time, it can take up to one week.<\/p>\n \nDuring this step rescue cells are also collected and stored at the hospital. These are your existing blood stem cells and are kept untreated just in case there is a problem in the treatment process. If CASGEVY cannot be given after the conditioningmedicine, or if the modified blood stem cells do not take hold (engraft) in the body, these rescue cells will be given back to you. If you are given rescue cells, you will not have any treatment benefit from CASGEVY.<\/p>\n STEP 2:<\/b> After they are collected, your blood stem cells will be sent to the manufacturing site where they are used to make CASGEVY. It may take up to 6 months from the time your cells are collected to manufacture and test CASGEVY before it is sent back to your healthcare provider.<\/p>\n STEP 3:<\/b> Shortly before your stem cell transplant, your healthcare provider will give you a conditioning medicine for a few days in hospital. This will prepare you for treatment by clearing cells from the bone marrow, so they can be replaced with the modified cells in CASGEVY. After you are given this medicine, your blood cell levels will fall to very low levels. You will stay in the hospital for this step and remain in the hospital until after the infusion with CASGEVY.<\/p>\n STEP 4:<\/b> One or more vials of CASGEVY will be given into a vein (intravenous infusion) over a short period of time.<\/p>\n \nAfter the CASGEVY infusion, you will stay in hospital so that your healthcare provider can closely monitor your recovery. This can take 4-6 weeks, but times can vary. Your healthcare provider will decide when you can go home.<\/p>\n What should I avoid after receiving CASGEVY?<\/b><\/p>\n What are the possible or reasonably likely side effects of CASGEVY?<\/b><\/p>\n \nThe most common side effects of CASGEVY include:<\/p>\n \nYour healthcare provider will test your blood to check for low levels of blood cells (including platelets and white blood cells). Tell your healthcare provider right away if you get any of the following symptoms:<\/p>\n \nThese are not all the possible side effects of CASGEVY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.<\/p>\n General information about the safe and effective use of CASGEVY<\/b><\/p>\n \nTalk to your healthcare provider about any health concerns.<\/p>\n \nPlease see full Prescribing Information<\/a> including Patient Information<\/a> for CASGEVY.<\/p>\n About Vertex<\/strong><\/p>\n \nVertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1.<\/p>\n \nVertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry’s top places to work, including 16 consecutive years on Science magazine’s Top Employers list and one of Fortune\u2019s 100 Best Companies to Work For. For company updates and to learn more about Vertex’s history of innovation, visit www.vrtx.com<\/a> or follow us on LinkedIn<\/a>, Facebook<\/a>, Instagram<\/a>, YouTube<\/a> and X<\/a>.<\/p>\n Special Note Regarding Forward-Looking Statements<\/b><\/p>\n \nThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, the statements by Ludovic Fenaux, in this press release, and statements regarding Vertex\u2019s expectations for the benefits of CASGEVY, expectations for access to CASGEVY for eligible patients in Germany, and Vertex\u2019s plans to continue working with government and reimbursement authorities globally to ensure sustainable access for eligible patients. While we believe the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company’s beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company’s development programs may not support registration or further development of its compounds due to safety, efficacy, and other reasons, anticipated patient populations may be different than expected, and other risks listed under the heading \u201cRisk Factors\u201d in Vertex’s most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at www.sec.gov<\/a> and available through the company’s website at www.vrtx.com<\/a>. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.<\/p>\n \n(VRTX-GEN)<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260424009095\/en\/<\/a><\/span><\/p>\n Vertex Pharmaceuticals Incorporated\n
\n
\n
\n
\n
\n
\n
\n
<\/p>\n
\n<\/b>
Investors:
\n<\/b>
InvestorInfo@vrtx.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260424009095\/en\/1093022\/3\/Vertex_Logo_colorRGB.jpg\"){kind=logo}
<\/td>\n<\/tr>\n